Search

Boris M Tabakoff

from Evergreen, CO
Age ~82
Get Report
Also known as:
Boris Living Tabakoff, Boris Revocable Tabakoff, Boris Lt Rt Tabakoff, Boris Te Tabakoff, Boris Tabakoff Boris Tabakoff, Boriss Tabakoff, Borris Tabakof, Borris S
Phone and address:
1177 Niagara St, Denver, CO 80220
(303) 333-7568
Related to:
Emelia Tabakoff, 74
Connected to:
Almir Tabakovic, 49Deian T Tabakov, 44Ibro I Tabakovic, 82Rifat Tabakovic, 66Mark G Tabal, 42Wanda B Tabalanza, 43Brian A Tabalba, 40Artemio S Tabales, 75Eliseo E Tabales, 48Dag Tabanag, 50

Boris Tabakoff Phones & Addresses

  • 1177 Niagara St, Denver, CO 80220 (303) 333-7568 (970) 736-8349 (303) 810-4828
  • Evergreen, CO
  • Annapolis, MD
  • 1352 E Schapville Rd, Elizabeth, IL 61028 (773) 845-2527 (815) 845-2527
  • 7456 E Townsend Rd, Stockton, IL 61085
  • Apple River, IL
  • Scales Mound, IL
  • Oak Creek, CO

Work

Company: University of colorado health sciences center Position: Professor

Industries

Research

Public records

Vehicle Records

Boris Tabakoff

View page
Address:
1177 Niagara St, Denver, CO 80220
Phone:
(303) 333-7568
VIN:
WMWMF73507TT85792
Make:
MINI
Model:
COOPER
Year:
2007

Resumes

Resumes

Boris Tabakoff Photo 1

Professor

View page
Location:
Denver, CO
Industry:
Research
Work:
University of Colorado Health Sciences Center
Professor

Publications

Us Patents

Compounds, Compositions And Method Suitable For Amelioration Of Withdrawal Syndromes And Withdrawal-Induced Brain Damage

View page
US Patent:
6962930, Nov 8, 2005
Filed:
Jun 5, 1998
Appl. No.:
09/171697
Inventors:
Boris Tabakoff - Elizabeth IL, US
Lawrence Snell - Aurora CO, US
Paula L. Hoffman - Denver CO, US
Assignee:
Lohocla Research Corporation - Denver CO
International Classification:
A61K031/4706
C07D215/42
A61P025/08
A61P025/22
US Classification:
514313, 546162
Abstract:
Compounds, composition and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e. g. ethanol, barbiturates, opiates etc. ). The combined actions of the disclosed compound on VSNaC and NMDA receptors also impart properties to these compounds that are important in preventing and reducing excitotoxic neurodegeneration and reducing anxiety without the undesirable CNS depressant side-effects of agents hitherto employed for these purposes.

Method For Treating Chronic Pain

View page
US Patent:
7923458, Apr 12, 2011
Filed:
Oct 6, 2006
Appl. No.:
12/083110
Inventors:
Boris Tabakoff - Elizabeth IL, US
Assignee:
Lohocla Research Corporation - Aurora CO
International Classification:
A01N 43/42
A61K 31/47
US Classification:
514312, 514313
Abstract:
A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e. g. , a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e. g. , ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.

Diagnostic Tests Of Substance Use Disorders

View page
US Patent:
8168402, May 1, 2012
Filed:
Nov 3, 2006
Appl. No.:
12/084306
Inventors:
Boris Tabakoff - Denver CO, US
Lawrence Snell - Aurora CO, US
Assignee:
Lohocla Research Corporation - Aurora CO
International Classification:
G01N 33/567
G01N 31/00
G01N 33/53
A61K 49/00
US Classification:
435 721, 435 71, 435 724, 436 10, 436 15, 436 63, 436811, 436901, 424 92
Abstract:
The present invention relates to compositions and methods for identifying and quantifying platelet proteins that relate to various bodily states. The present invention further provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.

Genetic Diagnosis Of Depression

View page
US Patent:
20040132062, Jul 8, 2004
Filed:
Sep 24, 2003
Appl. No.:
10/670452
Inventors:
Boris Tabakoff - Denver CO, US
Larry Martinez - Edmonds WA, US
Assignee:
The Regents of the University of Colorado, a body corporate - Boulder CO
International Classification:
C12Q001/68
C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention relates to compositions and methods for determining whether an individual is predisposed to depression. In particular, the present invention provides a genetic marker useful alone or in combination with other genetic markers for the diagnosis, characterization and treatment of depression

Genetic Diagnosis Of Alcoholism Subtypes

View page
US Patent:
20040180370, Sep 16, 2004
Filed:
Jan 27, 2004
Appl. No.:
10/766590
Inventors:
Boris Tabakoff - Denver CO, US
Larry Martinez - Colorado Springs CO, US
Paula Hoffman - Denver CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate - Boulder CA
International Classification:
C12Q001/68
C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention relates to compositions and methods for determining whether an individual is predisposed to or protected from alcoholism. In particular, the present invention provides genetic markers useful for the diagnosis, characterization, and treatment or prevention of alcohol tolerance, abuse and/or dependence.

Compositions And Methods For The Treatment Of Schizophrenia And Addictive Disorders

View page
US Patent:
20050048042, Mar 3, 2005
Filed:
Jun 24, 2004
Appl. No.:
10/877654
Inventors:
Boris Tabakoff - Denver CO, US
Michael Zawada - Denver CO, US
Masami Yoshimura - Denver CO, US
Paula Hoffman - Denver CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
International Classification:
A61K048/00
C12N005/08
US Classification:
424093210, 435368000
Abstract:
The present invention relates to compositions and methods for regulating neurotransmitter activity in the brains of patients with schizophrenia and addictive disorders. In particular, the present invention provides treatments directed at reducing dopaminergic overactivity.

Genetic Diagnosis Of Depression

View page
US Patent:
20100273153, Oct 28, 2010
Filed:
Nov 21, 2007
Appl. No.:
12/516554
Inventors:
Boris Tabakoff - Denver CO, US
Larry Martinez - Edmonds WA, US
Laura Saba - Parker CO, US
Paula Hoffman - Denver CO, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to compositions and methods for determining whether an individual is predisposed to major depressive disorder and/or to bipolar disorder. In particular, the present invention provides genetic markers useful alone or in combination with other genetic markers for the diagnosis, characterization and treatment of major (unipolar) depression and/or bipolar disorder.

Method For Treating Peripheral Neuropathic Pain

View page
US Patent:
20110184018, Jul 28, 2011
Filed:
Apr 7, 2011
Appl. No.:
13/081641
Inventors:
Boris TABAKOFF - Elizabeth IL, US
Assignee:
LOHOCLA RESEARCH CORPORATION - Aurora CO
International Classification:
A61K 31/4706
A61P 25/00
US Classification:
514313
Abstract:
A method for the treatment of peripheral neuropathic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from peripheral neuropathic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds. The diphenylureido-dihalokynurenate compounds are shown to be agonists of cannabinoid receptor 1 (CB1) and stimulate CB1 activity.

Isbn (Books And Publications)

Alcohol Research from Bench to Bedside

View page
Author

Boris Tabakoff

ISBN #

0866568522

Control profile
Boris M Tabakoff from Evergreen, CO, age ~82 Get Report